Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Sales & Marketing
Transparency

Is pure play pharma's new pharmakon?

The shift in commercial teams has been happening for some time. This is not new news. I have felt it many times over, like many of us who have worked in the industry for years.

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. MSD, Moderna skin cancer vaccine scores historic phase 3 win
  2. Trump taps White House aide Heidi Overton to lead FDA
  3. Sandoz adds 10 biosimilars through $322m Henlius deal
  4. Claude Science outperforms experts in protein binder task
  5. Sanofi to lay off 229 Blueprint employees, close offices

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more